Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1993 6
1994 9
1995 12
1996 18
1997 16
1998 26
1999 17
2000 12
2001 15
2002 9
2003 11
2004 12
2005 9
2006 13
2007 5
2008 6
2009 5
2010 2
2011 2
2013 2
2014 4
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Results by year

Filters applied: . Clear all
Page 1
The clinical development of 9-aminocamptothecin.
Takimoto CH, Thomas R. Takimoto CH, et al. Ann N Y Acad Sci. 2000;922:224-36. doi: 10.1111/j.1749-6632.2000.tb07041.x. Ann N Y Acad Sci. 2000. PMID: 11193898 Review.
9-Aminocamptothecin (9-AC) is a topoisomerase I-targeting agent first synthesized by Wani and Wall in 1986. ...
9-Aminocamptothecin (9-AC) is a topoisomerase I-targeting agent first synthesized by Wani and Wall in 1986. ...
Clinical applications of the camptothecins.
Takimoto CH, Wright J, Arbuck SG. Takimoto CH, et al. Biochim Biophys Acta. 1998 Oct 1;1400(1-3):107-19. doi: 10.1016/s0167-4781(98)00130-4. Biochim Biophys Acta. 1998. PMID: 9748525 Review.
Newer camptothecin analogs in clinical development, such as 9-aminocamptothecin, 9-nitrocamptothecin, GI147211 and DX-8951f, are also being studied to determine if they have improved toxicity and efficacy profiles compared with existing analogs. Other potenti …
Newer camptothecin analogs in clinical development, such as 9-aminocamptothecin, 9-nitrocamptothecin, GI147211 and DX-8 …
Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors.
Lamond JP, Wang M, Kinsella TJ, Boothman DA. Lamond JP, et al. Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):369-76. doi: 10.1016/s0360-3016(96)00326-4. Int J Radiat Oncol Biol Phys. 1996. PMID: 8892462 Review.
PURPOSE: Preclinical studies have demonstrated differences in potency, solubility, and tumor specific activity among the camptothecin (CPT) analogues. 9-Aminocamptothecin (9-AC) has demonstrated greater potency in animal studies than other clinically availabl …
PURPOSE: Preclinical studies have demonstrated differences in potency, solubility, and tumor specific activity among the camptothecin …
Clinical pharmacology of camptothecins.
Iyer L, Ratain MJ. Iyer L, et al. Cancer Chemother Pharmacol. 1998;42 Suppl:S31-43. doi: 10.1007/s002800051077. Cancer Chemother Pharmacol. 1998. PMID: 9750027 Review.
Camptothecins (CPTs) are a unique class of chemotherapeutic agent which inhibit DNA synthesis by inhibiting topoisomerase I activity. Structure-activity studies on the original CPT alkaloid led to the development of the new analogues irinotecan (CPT-11), topotecan, and …
Camptothecins (CPTs) are a unique class of chemotherapeutic agent which inhibit DNA synthesis by inhibiting topoisomerase I activity. …
A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, Bartel S, Levy S, Rosowsky A, Toppmeyer D, et al. Rubin E, et al. Clin Cancer Res. 1995 Mar;1(3):269-76. Clin Cancer Res. 1995. PMID: 9815982 Clinical Trial.
Camptothecins are the only available antitumor agents which target the nuclear enzyme topoisomerase I. 9-Aminocamptothecin (9-AC) is a water-insoluble derivative of camptothecin which has demonstrated impressive antitumor activity in preclinical models …
Camptothecins are the only available antitumor agents which target the nuclear enzyme topoisomerase I. 9-Aminocamptothecin …
Alternative administration of camptothecin analogues.
Glaberman U, Rabinowitz I, Verschraegen CF. Glaberman U, et al. Expert Opin Drug Deliv. 2005 Mar;2(2):323-33. doi: 10.1517/17425247.2.2.323. Expert Opin Drug Deliv. 2005. PMID: 16296757 Review.
In order to improve the therapeutic index of camptothecin (CPT) analogues, alternative administration of CPT analogues is being evaluated. Topotecan, irinotecan, rubitecan, lurtotecan and 9-aminocamptothecin have been administered orally with response rates e …
In order to improve the therapeutic index of camptothecin (CPT) analogues, alternative administration of CPT analogues is being evalu …
9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer.
de Souza PL, Cooper MR, Imondi AR, Myers CE. de Souza PL, et al. Clin Cancer Res. 1997 Feb;3(2):287-94. Clin Cancer Res. 1997. PMID: 9815685
9-Aminocamptothecin (9-AC) is a topoisomerase I inhibitor currently being developed as an antineoplastic agent. ...
9-Aminocamptothecin (9-AC) is a topoisomerase I inhibitor currently being developed as an antineoplastic agent. ...
Current perspectives on camptothecins in cancer treatment.
Dancey J, Eisenhauer EA. Dancey J, et al. Br J Cancer. 1996 Aug;74(3):327-38. doi: 10.1038/bjc.1996.362. Br J Cancer. 1996. PMID: 8695345 Free PMC article. Review.
Broad anti-tumour activity shown in preclinical studies has been confirmed in phase I/II studies for irinotecan and topotecan. Two other derivatives, 9-aminocamptothecin and GI 147211C, are undergoing phase I and early phase II evaluation. ...Small-cell lung cancer …
Broad anti-tumour activity shown in preclinical studies has been confirmed in phase I/II studies for irinotecan and topotecan. Two other der …
Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice.
Prijovich ZM, Chen BM, Leu YL, Chern JW, Roffler SR. Prijovich ZM, et al. Br J Cancer. 2002 May 20;86(10):1634-8. doi: 10.1038/sj.bjc.6600317. Br J Cancer. 2002. PMID: 12085215 Free PMC article.
Beta-glucuronidase activated 9-aminocamptothecin glucuronide to produce similar cell killing as 9-aminocamptothecin or topotecan. The in vivo toxicity of 9-aminocamptothecin glucuronide in BALB/c mice was dose-, route-, sex- and age-depen …
Beta-glucuronidase activated 9-aminocamptothecin glucuronide to produce similar cell killing as 9-aminocamptothecin …
Camptothecins: a review of their chemotherapeutic potential.
Ulukan H, Swaan PW. Ulukan H, et al. Drugs. 2002;62(14):2039-57. doi: 10.2165/00003495-200262140-00004. Drugs. 2002. PMID: 12269849 Review.
In general, camptothecins are not substrates for either the multidrug-resistance P-glycoprotein or the multidrug-resistance-associated protein (MRP). ...This review illustrates the proposed mechanism(s) of action of camptothecins and presents a concise overview of c …
In general, camptothecins are not substrates for either the multidrug-resistance P-glycoprotein or the multidrug-resistance-associate …
200 results